Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma
<b>Objectives:</b> This in vivo study introduces a newly developed spirooxindole derivative that is deemed safe and effective as a potential targeted therapy for various cancers. <b>Methods:</b> Extensive in vivo investigations, including histopathology, immunohistochemistry,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/93 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587702671769600 |
|---|---|
| author | Assem Barakat Fardous F. El-Senduny Mohammad Shahidul Islam Abdullah Mohammed Al-Majid Yaseen A. M. M. Elshaier Eman A. Mazyed Farid A. Badria |
| author_facet | Assem Barakat Fardous F. El-Senduny Mohammad Shahidul Islam Abdullah Mohammed Al-Majid Yaseen A. M. M. Elshaier Eman A. Mazyed Farid A. Badria |
| author_sort | Assem Barakat |
| collection | DOAJ |
| description | <b>Objectives:</b> This in vivo study introduces a newly developed spirooxindole derivative that is deemed safe and effective as a potential targeted therapy for various cancers. <b>Methods:</b> Extensive in vivo investigations, including histopathology, immunohistochemistry, and molecular biology, validated its potential for further preclinical and clinical exploration, necessitating comprehensive examinations of its bioavailability, pharmacodynamics, and pharmacokinetics. Additionally, this study involves the development of a commercially viable proniosomal drug delivery system for the compound, facilitating controlled drug release. <b>Results:</b> The data revealed efficacy of spirooxindole derivative in halting the progression of liver cancer, metastasis, and portal vein thrombosis, with potential implications for enhancing regeneration and recovery of early-stage cancer cells in multiple organs, thereby improving recovery rates and remission among cancer patients. The proniosomes, loaded with the compound, exhibited high entrapment efficiency and prolonged drug release rates of up to 12 h in vitro. The optimized formula demonstrated superior drug release percentages and stability compared to conventional niosomes. Further analysis via FTIR and DSC confirmed the absence of chemical interactions and proper entrapment of the compound within the nanovesicles, indicating a stable and effective drug delivery system. <b>Conclusions:</b> This study presents a novel, safe, and effective chemical entity of spirooxindole derivatives for further preclinical and clinical studies. |
| format | Article |
| id | doaj-art-36d2be905117425e9f927ab8b1c4dac9 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-36d2be905117425e9f927ab8b1c4dac92025-01-24T13:45:56ZengMDPI AGPharmaceutics1999-49232025-01-011719310.3390/pharmaceutics17010093Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular CarcinomaAssem Barakat0Fardous F. El-Senduny1Mohammad Shahidul Islam2Abdullah Mohammed Al-Majid3Yaseen A. M. M. Elshaier4Eman A. Mazyed5Farid A. Badria6Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi ArabiaDepartment of Pathology & Laboratory Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL 33136, USADepartment of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi ArabiaDepartment of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi ArabiaDepartment of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Menoufiya 32958, EgyptDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Kaferelsheikh University, Kaferelsheikh 33516, EgyptDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt<b>Objectives:</b> This in vivo study introduces a newly developed spirooxindole derivative that is deemed safe and effective as a potential targeted therapy for various cancers. <b>Methods:</b> Extensive in vivo investigations, including histopathology, immunohistochemistry, and molecular biology, validated its potential for further preclinical and clinical exploration, necessitating comprehensive examinations of its bioavailability, pharmacodynamics, and pharmacokinetics. Additionally, this study involves the development of a commercially viable proniosomal drug delivery system for the compound, facilitating controlled drug release. <b>Results:</b> The data revealed efficacy of spirooxindole derivative in halting the progression of liver cancer, metastasis, and portal vein thrombosis, with potential implications for enhancing regeneration and recovery of early-stage cancer cells in multiple organs, thereby improving recovery rates and remission among cancer patients. The proniosomes, loaded with the compound, exhibited high entrapment efficiency and prolonged drug release rates of up to 12 h in vitro. The optimized formula demonstrated superior drug release percentages and stability compared to conventional niosomes. Further analysis via FTIR and DSC confirmed the absence of chemical interactions and proper entrapment of the compound within the nanovesicles, indicating a stable and effective drug delivery system. <b>Conclusions:</b> This study presents a novel, safe, and effective chemical entity of spirooxindole derivatives for further preclinical and clinical studies.https://www.mdpi.com/1999-4923/17/1/93spirooxindolenanoformulationp53-MDM2cancer researchhepatocellular carcinoma |
| spellingShingle | Assem Barakat Fardous F. El-Senduny Mohammad Shahidul Islam Abdullah Mohammed Al-Majid Yaseen A. M. M. Elshaier Eman A. Mazyed Farid A. Badria Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma Pharmaceutics spirooxindole nanoformulation p53-MDM2 cancer research hepatocellular carcinoma |
| title | Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma |
| title_full | Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma |
| title_fullStr | Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma |
| title_full_unstemmed | Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma |
| title_short | Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma |
| title_sort | nanoformulation of spirooxindole and methods for treating hepatocellular carcinoma |
| topic | spirooxindole nanoformulation p53-MDM2 cancer research hepatocellular carcinoma |
| url | https://www.mdpi.com/1999-4923/17/1/93 |
| work_keys_str_mv | AT assembarakat nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma AT fardousfelsenduny nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma AT mohammadshahidulislam nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma AT abdullahmohammedalmajid nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma AT yaseenammelshaier nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma AT emanamazyed nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma AT faridabadria nanoformulationofspirooxindoleandmethodsfortreatinghepatocellularcarcinoma |